Background: Glucagon-like peptide 1 agonists differ in chemical structure, duration of action and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. Methods: We randomly assigned patients with type 2 diabetes and cardiovascular disease to the addition of once-weekly subcutaneous injection of albiglutide (30 mg to 50 mg) or matching placebo to standard care. We hypothesized that albiglutide would be noninferior to placebo for the primary outcome of first occurrence of cardiovascular death, myocardial infarction, or stroke. If noninferiority was confirmed by an upper limit of the 95% confidence interval for the hazard ratio of less than 1.30, closed-testing for superiority was prespecified. Findings: Overall, 9463 participants were followed for a median of 1.6 years. The primary composite outcome occurred in 338 of 4731 patients (7.1%; 4.6 events per 100 person-years) in the albiglutide group and in 428 of 4732 patients (9.0%; 5.9 events per 100 person-years) in the placebo group (hazard ratio, 0.78; 95% confidence interval [CI ], 0.68 to 0.90), indicating that albiglutide, was superior to placebo (P<0.0001 for noninferiority, P=0.0006 for superiority). The incidence of acute pancreatitis (albiglutide 10 patients and placebo 7 patients), pancreatic cancer (6 and 5), medullary thyroid carcinoma (0 and 0), and other serious adverse events did not differ significantly between the two groups. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. (Funded by GlaxoSmithKline; Harmony Outcomes ClinicalTrials.gov number, NCT02465515.) noninferiority; P = 0.06 for superiority). There seems to be variation in the results of existing trials with GLP-1 receptor agonists, which if correct, might reflect drug structure or duration of action, patients studied, duration of follow-up or other factors.
Objective: Determine the effect of physical activity on vitamin D (vitD) status in pregnant women. Design/Methods: Women who presented at 10-14 weeks' gestation participated in vitD supplementation RCT, conducted between November 2012 and June 2016, were randomized into one of two treatment groups: 400 or 4400 IU/day of vitD3. VitD status, as defined by total circulating 25(OH)D concentration, was measured monthly. Physical activity was measured monthly using the Paffenbarger Questionnaire, and responses were categorized as vigorously exercising for ≥ 2.5 h/week during each trimester. Sunlight exposure was measured using skin spectrophotometry (SmartProbe 400). Linear regression and mixed models explored the association of maternal 25(OH)D concentration, sunlight exposure, physical activity, race, treatment group, body mass index, perceived stress score, and visit using SAS software (version 9.4). Results: 211 pregnant women had physical activity information available. At baseline, vigorously exercising ≥ 2.5 h/week was associated with being older (p=0.0004), white/Caucasian (p=0.011), privately insured (p=0.018), and purposefully pregnant (p<0.031). Baseline 25(OH)D did not vary by treatment or exercise groups. In bivariate analysis, at second trimester, vigorously exercising ≥ 2.5 h/week was associated with being white/Caucasian, privately insured, purposefully pregnant, married and with higher 25(OH)D concentration. By third trimester, vigorous exercise was associated with being privately insured, married, gravidity, sunlight exposure and Hispanic. The effect of increased exercise on 25(OH)D concentration was seen only in the 400 IU group at third trimester. In a mixed model controlling for multiple potential confounders, maternal vitD status and exercise were positively associated (p=0.018). Conclusion: Independent of sunlight exposure, pregnant women who vigorously exercised ≥ 2.5 h/week had higher 25(OH)D concentrations than those who did not. Supplementation may have overshadowed the exercise effect; the positive correlation was amplified when looking at the 400 IU group alone, and may suggest that exercise was more critical for those lacking the higher supplementation dose.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.